In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
San Diego, USA-headquartered Conduit Pharmaceuticals, a disease agnostic life science company, today announced the appointment of Dr Joanne Holland as chief scientific officer (CSO). 19 March 2024
Biotechnology
San-Diego Contineum Therapeutics, biotech developing small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications, is going public. 19 March 2024
Biotechnology
Samsung Life Science Fund announced Samsung’s investment in Boston, USA-based BrickBio, a pre-clinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code. 19 March 2024
Pharmaceutical
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house. 19 March 2024
Pharmaceutical
German pharma major Bayer has announced positive top-line results from the Phase III OASIS 3 trial, adding to the successes of OASIS 1 and 2 earlier this year. 19 March 2024
Pharmaceutical
Shares of Canada-headquartered Fusion Pharmaceuticals were up more than 95% at $20.80 in pre-market activity, on the news of a takeover bid from UK pharma major AstraZeneca. 19 March 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted the resubmission of US critical care specialist Citius Pharmaceuticals’ Biologics License Application (BLA) for Lymphir (denileukin diftitox). 19 March 2024
Pharmaceutical
US radiopharmaceuticals-focussed company Lantheus Holdings has announced the promotion of Amanda Morgan to chief commercial officer (CCO) and her elevation to be a member of the company’s executive team, effective March 25, 2024. 19 March 2024
Pharmaceutical
Parexel, one of the world’s largest clinical research organizations (CROs), has announced a change at the top. 18 March 2024
Pharmaceutical
Mitsubishi Tanabe Pharma America has announced the publication of results in The Lancet Neurology from the pivotal, Phase III BouNDless trial. 18 March 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DFD-29 (minocycline hydrochloride modified release capsules, 40mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. 18 March 2024
Biosimilars
The US unit of South Korea’s Celltrion today announced the availability of Zymfentra (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab. 18 March 2024
Biotechnology
A new chief medical officer will take the reins at Shanghai-based biotech Everest Medicines, as the drug and vaccine firm undertakes a minor reshuffle at the top. 18 March 2024
Biotechnology
UK pharma major GSK (LSE: GSK) updated on the development of its Jemperli (dostarlimab) at the Society of Gynecologic Oncology 2024 Annual Meeting on Women’s Cancer on March 16. 18 March 2024
Pharmaceutical
In the UK, research originating from Cambridge University has received a significant vote of confidence from investors banking on the therapeutic potential of mitochondria. 18 March 2024
Pharmaceutical
US speciality drugmaker Fennec Pharmaceuticals and Norgine today announced an exclusive licensing agreement under which Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia and New Zealand. 18 March 2024
Biotechnology
Clinical-stage biotech Biotheus has entered into a collaboration with fellow China-based Hansoh Pharmaceutical following their current partnership since 2022. 18 March 2024
Biotechnology
It is 10 years since the deadliest Ebola virus disease outbreak that killed more than 11,000 people in West Africa. 18 March 2024
Pharmaceutical
Japanese drugmaker Sumitomo Pharma and its US subsidiary Sumitomo Pharma America have amended a collaboration with Otsuka Pharmaceuticals. 18 March 2024
Pharmaceutical
March is designated multiple system atrophy (MSA) awareness month, which we have taken as an opportunity to delve into advances in treatment for this rare disorder. 18 March 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze